Zydus receives approvals from the USFDA for Doxycycline Hyclate Delayed-Release Tablets and Febuxostat Tablets

Zydus receives approvals from the USFDA for Doxycycline Hyclate Delayed-Release Tablets and Febuxostat Tablets Ahmedabad, 24 December, 2018 Zydus Cadila has received the final approval from the USFDA to market Doxycycline Hyclate Delayed-Release Tablets USP (US RLD – Doryx®) in the strengths of 75 mg, 100 mg and 150 mg. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad. This medication is used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. The group also received a tentative approval for Febuxostat Tablets (US RLD – Uloric), 40 mg and 80 mg . It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad. It is used to treat hyperuricemia (constantly high levels of uric acid) in adults who have gout. It helps in decreasing symptoms of gout which include pain, swelling, redness, heat, soreness, and stiffness in certain joints. The group now has 2 41 approvals and has so far filed over 340 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Cadila Zydus Cadila i s an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare ther apies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020. ***

The release as fetched from its publisher. zyduslife.com ↗